On AI-driven transformation in drug discovery, pharma, and healthcare — grounded in a decade of tracking this space.
The third annual edition, covering agentic AI systems and the clinical-stage pipeline — the definitive read on where AI in drug discovery actually stands.
Analysis of GLP-1 receptor agonists' impact on pharmaceutical strategy and healthcare economics — one of the defining forces reshaping the industry.
Beyond published reports, we take on select analytical engagements for VCs, corporate strategy, and scouting teams — landscape sense-making built on judgment nobody can scrape.